The Centre for Process Innovation (CPI) today announced that they have
secured a multi-million pound investment via the Government’s Advanced
Manufacturing Supply Chain Initiative (AMSCI) to support the development and
manufacture of novel biologic treatments.
The £6.2m investment will go towards the estimated total cost of the
project which is around £11.3m.
which is a joint bid with five other UK based organisations including UCB
Celltech and Lonza Biologics, aims to overcome some of the most significant
shortcomings of the current biologics supply chain and enable the continued
delivery of cost effective therapies to patients. As a key member of the High Value
Manufacturing Catapult, CPI will supply technical expertise, facilities, and
project management through the newly created National Biologics Manufacturing
Centre (NBMC) based at Darlington.
will achieve its aims by adopting leading-edge technologies emerging from UK
SMEs to target critical points in the biologics supply chain. Single cell
analysis and cell sorting technology from Sphere
Fluidics will increase the productivity of antibody analysis and
development and lead to more high quality candidates entering clinical trials. Horizon Discovery will apply their gene editing
technology to deliver flexible, low cost and efficient cellular systems to
support the future needs of biologics manufacture. Alcyomics
Ltd will contribute a novel tool to predict biologics safety and work with CPI, Lonza and UCB to establish methods and approaches to choose candidates with
the lowest risk of failure.
outcome of the project is to reduce the time it takes to bring biologics to
market by increasing our ability to identify failing drugs earlier in development (i.e. those candidates likely to fail due to safety,
manufacturing or formulation difficulties).
of manufacturing systems for the next generation of biologics molecules will be
vastly improved. Additionally, the project proposes to create 23 new job opportunities
and safeguard 174 existing jobs by March 2022.
Dowle, Director of Biologics at CPI said “We
are delighted to have received the government’s support on this project. The
consortium of companies behind this project is well-equipped to streamline the
development process of biologics. The increasing emphasis on stratified
medicines means that supply chains that were initially designed to deliver a
few traditional blockbusters in large quantities must be adapted to develop and
manufacture a higher number of diverse therapies. Our goal is to find
innovative ways to make this transition while also ensuring affordability.”
“Our goal is to help
integrate in a seamless way the design and selection of lead therapeutic
candidates with novel approaches to process development and manufacturing,
which is expected to help streamline bio-therapeutic development and improve
its efficiency compared with existing practices in the industry,” said Marc Funk,
COO of Lonza’s Pharma&Biotech segment.
“Further, the project aims to strengthen the biotechnology ecosystem in the UK
by developing closer interactions between technology innovators, pharmaceutical
companies, contract research and manufacturing organisations, and health care
providers – all of whom are working towards a common goal.”